Other MAPKs, such as p38, c-Jun N-terminal kinase (JNK), and transforming growth factor beta-activated kinase 1 (TAK1), are activated in asthma and COPD129, and inhibitors of these targets can mitigate various features of AR in both cell and animal asthma models90–95. Here, MAP3K7 is linked to asthma.